Super-enhancers are found to be associated with BRD4 at overactive genes in several pathologies, e.g. cancer progression (Whyte et al., 2013, Loven et al., 2013), EC activation (Brown et al., 2014), and cardiomyocyte hypertrophy (Anand et al., 2013). The gene discussed is BRD4; the disease is cancer.